Dozens of opportunities for US generic competition have been highlighted by the US Food and Drug Administration in the latest update to the agency’s list of off-patent products without exclusivities that nevertheless have no approved generic rivals.
FDA Highlights Off-Patent Opportunities
Latest Update To List Of Products Open To Competition With No Rivals
Opportunities for generic competition have been highlighted by the FDA, in the latest update to its list of products that are not protected by patents or exclusivities but have no approved rivals.
